摘要
目的 探讨Septin-9和HIF-1α在宫颈癌组织中的表达及其临床意义。方法 对99例宫颈癌组织、50例宫颈上皮内瘤变组织及20例正常宫颈组织进行免疫组织化学染色,观察Septin-9、HIF-1α在各组织中的表达水平,并分析Septin-9、HIF-1α表达水平与宫颈癌患者临床病理指标的相关性。结果 单因素分析显示,宫颈病变与患者发病年龄、HPV感染及分型、绝经情况、孕次相关(P<0.05)。免疫组织化学结果显示,Septin-9、HIF-1α在宫颈癌组织中的表达水平显著升高(P<0.05)。Septin-9、HIF-1α在宫颈癌组织中的表达强度与患者的临床分期、淋巴结转移、肌层浸润相关(P<0.05),与年龄、病理分级、病理分型无关(P>0.05)。相关性分析显示,Septin-9与HIF-1α在宫颈癌组织中的表达存在显著正相关(r=0.671,P<0.05)。结论 Septin-9、HIF-1α在宫颈癌中显著高表达,可能通过协同作用来促进宫颈癌的发生与发展。
Objective To investigate the expression of Septin-9 and HIF-1αin cervical cancer tissues and their clinical significance.Methods Immunohistochemical staining was performed on 99 cervical cancer tissues,50 cervical intraepithelial neoplasia tissues and 20 normal cervical tissues;the expression levels of Septin-9 and HIF-1αwere observed in the above tissues;the correlation between the expression levels of Septin-9 and HIF-1αand clinical pathological indexes of cervical cancer was analyzed.Results Univariate analysis suggested that cervical lesions were associated with patients'age of onset,HPV infection and type,menopausal status,and number of pregnancies(P<0.05).Immunohistochemical results indicated that the expression levels of Septin-9 and HIF-1αwere significantly elevated in cervical cancer tissues(P<0.05).The expression intensity of Septin-9 and HIF-1αin cervical cancer tissues was correlated with clinical stage,lymph node metastasis,and muscle infiltration of the patients(P<0.05),and was not related to age,pathological grade,and pathological type(P>0.05).Correlation analysis revealed that there was a significant positive correlation between the expression of Septin-9 and HIF-1αin cervical cancer tissues(r=0.671,P<0.05).Conclusion Septin-9 and HIF-1αwere observed to be highly expressed in cervical cancer,and their synergistic effects might promote cervical carcinogenesis and progression.
作者
张元媛
罗国安
万俊辉
蔡德胜
陈琦
ZHANG Yuan-yuan;LUO Guo-an;WAN Jun-hui;CAI De-sheng;CHEN Qi(Department of Obstetrics and Gynecology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,China)
出处
《实用临床医学(江西)》
CAS
2024年第3期33-38,F0004,共7页
Practical Clinical Medicine
基金
国家自然科学基金地区基金项目(81560247)
江西省中医药管理局科技计划(2022Z020)
江西省卫生健康委员科技计划项目(202410189)。